Enzyme Replacement Therapy Proves Safe and Stable in Chinese Patients with Fabry Disease
A 52-week phase 3 trial across six Chinese centers found agalsidase alfa was generally well tolerated, kept kidney and cardiac ...
A 52-week phase 3 trial across six Chinese centers found agalsidase alfa was generally well tolerated, kept kidney and cardiac ...
A 60-week phase 3 trial found that once-daily tapinarof cream 0.5% significantly outperformed vehicle and maintained efficacy and safety in ...
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
A Phase 3 trial found that cesium-131 collagen tiles implanted during brain metastasis surgery reduced one-year recurrence to 1.3 percent ...
A two-stage estimation analysis of the CheckMate 9ER trial shows that removing the influence of subsequent therapy substantially enlarges the ...
The phase 3 evERA study found that an all-oral combination of the next-generation estrogen receptor degrader giredestrant and everolimus significantly ...
The Danish DALIAH phase 3 trial found that low-dose pegylated interferon achieved superior long-term molecular responses to hydroxyurea in myeloproliferative ...
The Phase 3 EVOKE-03/KEYNOTE-D46 trial found that sacituzumab govitecan plus pembrolizumab did not significantly improve progression-free or overall survival compared ...
The PACT-21/CASSANDRA phase 3 trial found that six months of preoperative chemotherapy produced event-free survival comparable to a four-month preoperative ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine